Janice W. Smith
Welwyn Garden City, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 18, 2026
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Journal: Journal of Alzheimer's disease : JAD
Published: December 17, 2024
Japanese participant data from three gantenerumab trials in early Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: September 25, 2024
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Journal: Journal of Alzheimer's disease : JAD
Published: August 23, 2024
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 23, 2024
Gantenerumab in Early Alzheimer's Disease. Reply.
Journal: The New England journal of medicine
Published: February 28, 2024
Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: February 08, 2024
Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease.
Journal: EClinicalMedicine
Published: December 22, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Journal: The New England journal of medicine
Published: November 15, 2023
Qualitative Exploration in Exit Interviews of Changes Observed in Clinical Trials for Individuals with Autism Spectrum Disorder Without Intellectual Disability.
Journal: Patient related outcome measures
Published: January 21, 2023
Quantitative and Qualitative Exploration of Meaningful Change on the Vineland Adaptive Behavior Scales (Vineland™-II) in Children and Adolescents with Autism Without Intellectual Disability Following Participation in a Clinical Trial.
Journal: Patient related outcome measures
Published: January 21, 2023
Last Updated: 09/26/2026